CIO Review Magazine has selected Code-N as a Top-20 Most Promising BioTech Solution Provider. We agree. The magazine selected us because of our ability to fundamentally change how to uncover new pathways to cures, provide scientific intelligence on competitors, repurpose drugs and alert drug makers of potential harmful interactions before going to trials. You can read more […]
Read more »We participated in Stanford University’s “Big Data in BioMedicine” conference the past few days here in Palo Alto. It was an invigorating 3 days of interactions with the worlds leading scientists, researchers, doctors, and technologists which furthers Code-N’s resolve to play a key role in this mission. As stated by Dr. Lloyd Minor, dean of the Stanford’s […]
Read more »Each year, Carlyle Conlan summarizes trends in the industry from a variety of sources including “grass roots” discussions with CEO’s, Venture Capitalists, Private Equity firms and Industry Analysts. Their report gets distributed to 14,000 Life Science professionals worldwide. The scope is broad and attempts to cover findings from early stage revolutionary research through shifts in […]
Read more »Roger Ulrich recently joined Code-N’s advisory board after completing the merger of the company he founded, Calistoga Pharmaceuticals, with Gilead Sciences. Be sure to also read commentaries by Dr. Christian Fibiger and Dr. Paul Pearson. As when we talked to Christian and Paul, we began by asking Roger what he views as the primary challenges in drug […]
Read more »Today we are delighted to introduce another key Code-N Advisory Board member: Dr. Paul Pearson. A veteran executive with Amgen, Merck, Pharmacia and Upjohn, Paul is now president of a consultancy advising biotechnology and pharmaceutical companies and the NIH on drug discovery, metabolism, drug interactions, toxicity, and safety. Be sure to read the profile of our […]
Read more »Code-N has recently added three distinguished executives to its advisory board. We’ll be introducing them and their specific takes on Code-N in upcoming blog posts. First up is Christian Fibiger, chief scientific officer at MedGenesis Therapeutix. We began by asking Chris about what he sees as the primary challenges impeding modern drug discovery and development. Databases […]
Read more »We got an email update the other day from the folks at Faster Cures. It was titled “A Journey of Innovation.” In fact, a form of the word “innovate” appeared 13 times in the introductory portion of the email. It sounded like a familiar mantra, one that we’ve been preaching since our inception.. We all […]
Read more »